Last reviewed · How we verify
ABL103
At a glance
| Generic name | ABL103 |
|---|---|
| Sponsor | ABL Bio, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors (PHASE1)
- ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |